RBC maintains Genentech at outperform

RBC Capital Markets analyst Jason Kantor kept Genentech, Inc. at outperform, average risk, after the company reported weaker-than-expected third-quarter sales of core oncology products and earnings per share of $0.59, above RBC's estimate of $0.52 and consensus of $0.50. Kantor remains positive on Genentech long term, given the company's robust pipeline, continued upside earnings per share and consistent execution. Shares of the South San Francisco, Calif.-based biotherapeutic company were down $1.45, or 1.69%, at $84.15. (NYSE: DNA)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.